上海宇玫博生物（Umibio）获得来自线性资本、苏高新科创天使基金数千万元天使轮融资，其中，线性资本领投。

上海宇玫博生物2016年成立于上海张江，专注基因编辑和外泌体核心技术的研发和商业化运营，是外泌体领域领军企业，也是上海市器官修复工程技术研究中心合作单位，荣获多项创新创业大赛优秀奖，拥有多项发明专利及30余项软件著作授权。

公司围绕外泌体开发的主线，解决了外泌体提纯、药物包裹、标记等技术难题，自主开发了外泌体锚定蛋白表达技术，提升外泌体药物载体的进程，并落地形成具有科研级及产业化能力的外泌体相关产品，是国内首批产业化成功的外泌体生物科技企业。

Introduction to Umibio

Umibio Science and Technology is a high-tech company specializing in exosome product development and technical services. Founded in 2015 in Zhangjiang High-Tech Park, Shanghai, it is a company engaged in exosome research, service and related reagent development in China, and has now developed into a supplier of exosome drug delivery and reagent solutions.

The company has 2,000 square meters of GMP standard factory workshop, instruments, facilities and equipments, having realized standardized and large-scale production and laying a solid foundation for entering the market.

The business scope includes research and development of novel drug delivery carriers, large-scale purification and production of exosome, research and development of exosome diagnostic reagents, and sales of exosome-relevant products, etc. The core technology has solved technical difficulties such as large-scale purification of exosome, exosome drug delivery and exosome labeling.

Currently, we have provided exosome products and technical services to Novo Nordisk, OBiO Technology, Genechem, JMT-BiO, Tsinghua University, Peking University, Zhejiang University, Fudan University, etc.

Contact:

Address: No.800 Qingdai Road, Pudong New Area, Shanghai

Tel.: 4006-166-973

Mailbox: umibio@umibio.cn

Company Name: Umibio Science and Technology Group

QQ: 3423485078

Website: www.umibio.cn